Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Jul 27

PMID 35885055

Authors

Seung Yong Park

Yasmin Hisham

Hyun Mu Shin

Su Cheong Yeom

Soohyun Kim

Affiliations

Soon will be listed here.

Abstract

Natural soluble antagonist and decoy receptor on the surface of the cell membrane are evolving as crucial immune system regulators as these molecules are capable of recognizing, binding, and neutralizing (so-called inhibitors) their targeted ligands. Eventually, these soluble antagonists and decoy receptors terminate signaling by prohibiting ligands from connecting to their receptors on the surface of cell membrane. Interleukin-18 binding protein (IL-18BP) participates in regulating both Th1 and Th2 cytokines. IL-18BP is a soluble neutralizing protein belonging to the immunoglobulin (Ig) superfamily as it harbors a single Ig domain. The Ig domain is essential for its binding to the IL-18 ligand and holds partial homology to the IL-1 receptor 2 (IL-1R2) known as a decoy receptor of IL-1α and IL-1β. IL-18BP was defined as a unique soluble IL-18BP that is distinct from IL-18Rα and IL-18Rβ chain. IL-18BP is encoded by a separated gene, contains 8 exons, and is located at chr.11 q13.4 within the human genome. In this review, we address the difference in the biological activity of IL-18BP isoforms, in the immunity balancing Th1 and Th2 immune response, its critical role in autoimmune diseases, as well as current clinical trials of recombinant IL-18BP (rIL-18BP) or equivalent.

Citing Articles

The Impact of Functional Promoter Variants in Interleukin-18 on Susceptibility to Rheumatoid Arthritis in Iranian Population.

Ramezanzadeh M, Khodabandehloo F, Alesaeidi S, Mousavi S, Sadeghi S, Ehtesham N Adv Biomed Res. 2024; 13:100.

PMID: 39717244 PMC: 11665170. DOI: 10.4103/abr.abr_29_24.

Advancements and challenges in immunocytokines: A new arsenal against cancer.

Shi W, Liu N, Lu H Acta Pharm Sin B. 2024; 14(11):4649-4664.

PMID: 39664443 PMC: 11628837. DOI: 10.1016/j.apsb.2024.07.024.

Effects of platelet-rich plasma combined with isometric quadriceps contraction on cartilage in a rat model of knee osteoarthritis.

Cheng L, Wang K, Chang S, Tan Y, He B Regen Ther. 2024; 26:469-477.

PMID: 39070125 PMC: 11283084. DOI: 10.1016/j.reth.2024.06.021.

Exploring the causal association between rheumatoid arthritis and the risk of cervical cancer: a two-sample Mendelian randomization study.

Xu M, Chen H, Tan T, Xie K, Xie H, Li Q Arthritis Res Ther. 2024; 26(1):35.

PMID: 38263277 PMC: 10804645. DOI: 10.1186/s13075-023-03240-2.

Markers of Inflammation, Tissue Damage, and Fibrosis in Individuals Diagnosed with Human Immunodeficiency Virus and Pneumonia: A Cohort Study.

Pena-Valencia K, Riano W, Herrera-Diaz M, Lopez L, Marin D, Gonzalez S Pathogens. 2024; 13(1).

PMID: 38251391 PMC: 10820350. DOI: 10.3390/pathogens13010084.

References

Conforti-Andreoni C, Spreafico R, Liang Qian H, Riteau N, Ryffel B, Ricciardi-Castagnoli P . Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18. J Immunol. 2011; 187(11):5842-50. DOI: 10.4049/jimmunol.1101408. View

Park J, Kim H, Lee J, Kim J, Jung K, Park Y . Natural killer cell cytolytic function in Korean patients with adult-onset Still's disease. J Rheumatol. 2012; 39(10):2000-7. DOI: 10.3899/jrheum.111500. View

Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D . Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly. 2002; 132(17-18):230-6. DOI: 10.4414/smw.2002.09941. View

Nazarian S, Rahman M, Werden S, Villeneuve D, Meng X, Brunetti C . Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. J Virol. 2007; 82(1):522-8. PMC: 2224402. DOI: 10.1128/JVI.00688-07. View

Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y . Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004; 50(6):1935-8. DOI: 10.1002/art.20268. View

Wawrocki S, Seweryn M, Kielnierowski G, Rudnicka W, Wlodarczyk M, Druszczynska M . IL-18/IL-37/IP-10 signalling complex as a potential biomarker for discriminating active and latent TB. PLoS One. 2019; 14(12):e0225556. PMC: 6903724. DOI: 10.1371/journal.pone.0225556. View

Iannello A, Boulassel M, Samarani S, Tremblay C, Toma E, Routy J . HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. J Infect Dis. 2010; 201(4):608-17. DOI: 10.1086/650314. View

Taylor T, Noguchi H, Totoki Y, Toyoda A, Kuroki Y, Dewar K . Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature. 2006; 440(7083):497-500. DOI: 10.1038/nature04632. View

Banda N, Vondracek A, Kraus D, Dinarello C, Kim S, Bendele A . Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol. 2003; 170(4):2100-5. DOI: 10.4049/jimmunol.170.4.2100. View

10.

Kiltz U, Kiefer D, Braun J, Schiffrin E, Girard-Guyonvarch C, Gabay C . Prolonged treatment with Tadekinig alfa in adult-onset Still's disease. Ann Rheum Dis. 2018; 79(1):e10. DOI: 10.1136/annrheumdis-2018-214496. View

11.

Fukaura H, Kikuchi S . [IL-18 in multiple sclerosis]. Nihon Rinsho. 2003; 61(8):1416-21. View

12.

Krumm B, Meng X, Wang Z, Xiang Y, Deng J . A unique bivalent binding and inhibition mechanism by the yatapoxvirus interleukin 18 binding protein. PLoS Pathog. 2012; 8(8):e1002876. PMC: 3426546. DOI: 10.1371/journal.ppat.1002876. View

13.

Wawrocki S, Seweryn M, Kielnierowski G, Rudnicka W, Druszczynska M . IL-18 and related function proteins associated with tuberculosis severity and screening for active TB among patients with non-mycobacterial community-acquired pneumonia (CAP). Saudi J Biol Sci. 2020; 27(11):3035-3045. PMC: 7569146. DOI: 10.1016/j.sjbs.2020.09.003. View

14.

Yasuda K, Nakanishi K, Tsutsui H . Interleukin-18 in Health and Disease. Int J Mol Sci. 2019; 20(3). PMC: 6387150. DOI: 10.3390/ijms20030649. View

15.

Lotito A, Campa A, Silva C, Kiss M, Mello S . Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol. 2007; 34(4):823-30. View

16.

Shao Q, Liu N, Li G, Meng Q, Yao J, Wang N . IL-18 expression in clinical human pituitary adenoma. Technol Health Care. 2021; 30(1):11-16. DOI: 10.3233/THC-191967. View

17.

Tong C, Li J, Lin W, Cen W, Zhang W, Zhu Z . Inhibition of heat shock protein 90 alleviates cholestatic liver injury by decreasing IL-1β and IL-18 expression. Exp Ther Med. 2021; 21(3):241. PMC: 7851627. DOI: 10.3892/etm.2021.9672. View

18.

Sasaki Y, Yoshimoto T, Maruyama H, Tegoshi T, Ohta N, Arizono N . IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity. J Exp Med. 2005; 202(5):607-16. PMC: 2212862. DOI: 10.1084/jem.20042202. View

19.

Canna S, de Jesus A, Gouni S, Brooks S, Marrero B, Liu Y . An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014; 46(10):1140-6. PMC: 4177369. DOI: 10.1038/ng.3089. View

20.

Carter S, Tattersall R, Ramanan A . Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2018; 58(1):5-17. DOI: 10.1093/rheumatology/key006. View